ArticleScientific reports2013
A universal protein tag for delivery of SiRNA-aptamer chimeras.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery.Pharmaceutics · 2021Article
- The Multifaceted Histidine-Based Carriers for Nucleic Acid Delivery: Advances and Challenges.Pharmaceutics · 2020Review
- Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?Molecular diagnosis & therapy · 2019Review
- Aptamers: Uptake mechanisms and intracellular applications.Advanced drug delivery reviews · 2018Review
- Aptamer-based targeted therapy.Advanced drug delivery reviews · 2018Review
- A ribonucleoprotein octamer for targeted siRNA delivery.Nature biomedical engineering · 2018Article
- Article
- Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.International journal of molecular sciences · 2017Review
- Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes.Biomedicines · 2017Review
- Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.Biomedicines · 2017Review
- A Simple Add-and-Display Method for Immobilisation of Cancer Drug on His-tagged Virus-like Nanoparticles for Controlled Drug Delivery.Scientific reports · 2017Article
- Functional peptides for siRNA delivery.Advanced drug delivery reviews · 2017Review
- Targeted Delivery of siRNA Therapeutics to Malignant Tumors.Journal of drug delivery · 2017Review
- Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.Theranostics · 2017Article
- Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.Scientific reports · 2016Article
- Analysis and Identification of Aptamer-Compound Interactions with a Maximum Relevance Minimum Redundancy and Nearest Neighbor Algorithm.BioMed research international · 2016Article
- Aptamer-Drug Conjugates.Bioconjugate chemistry · 2015Review
- Selective Targeting to Glioma with Nucleic Acid Aptamers.PloS one · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
siRNA-aptamer chimeras have emerged as one of the most promising approaches for targeted delivery of siRNA due to the modularity of their diblock RNA structure, relatively lower cost over other targeted delivery approaches, and, most importantly, the outstanding potential for clinical translation. However, additional challenges must be addressed for efficient RNA interference (RNAi), in particular, endosomal escape. Currently, vast majority of siRNA delivery vehicles are based on cationic materials, which form complexes with negatively charged siRNA. Unfortunately, these approaches complicate the formulations again by forming large complexes with heterogeneous sizes, unfavorable surface charges, colloidal instability, and poor targeting ligand orientation. Here, we report the development of a small and simple protein tag that complements the therapeutic and targeting functionalities of chimera with two functional domains: a dsRNA binding domain (dsRBD) for siRNA docking and a pH-dependent polyhistidine to disrupt endosomal membrane. The protein selectively tags along the siRNA block of individual chimera, rendering the overall size of the complex small, desirable for deep tissue penetration, and the aptamer block accessible for target recognition. More interestingly, we found that extending the c-terminal polyhistidine segment in the protein tag to 18 amino acids completely abolishes the RNA binding function of dsRBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.